Literature DB >> 22106077

Antipsychotic medication use among children and risk of diabetes mellitus.

Susan E Andrade1, Joan C Lo, Douglas Roblin, Hassan Fouayzi, Daniel F Connor, Robert B Penfold, Malini Chandra, George Reed, Jerry H Gurwitz.   

Abstract

OBJECTIVE: To assess whether the risk of incident diabetes was increased with the use of second-generation antipsychotics (SGAs) in a large diverse cohort of children.
METHODS: A retrospective study was conducted by using the administrative databases of 3 health plans participating in the Health Maintenance Organization Research Network. Children 5 to 18 years of age who initiated SGA therapy between January 2001 and December 2008 and 2 comparison groups, namely, nonusers of psychotropic drugs and users of antidepressant medications, were identified. Diagnoses from inpatient and outpatient records, pharmacy dispensings, and outpatient laboratory results were used to identify incident cases of diabetes.
RESULTS: The crude incidence rate of diabetes for the SGA-exposed cohort was 3.23 cases per 1000 person-years (95% confidence interval [CI]: 1.67-5.65), compared with 0.76 cases per 1000 person-years (95% CI: 0.49-1.12) among nonusers of psychotropic medications and 1.86 cases per 1000 person-years (95% CI: 1.12-2.90) among antidepressant users. The risk of incident diabetes was significantly increased among SGA users (unadjusted incidence rate ratio: 4.24 [95% CI: 1.95-8.72]) in comparison with nonusers of psychotropic medications but was not significantly increased in comparison with antidepressant medication users (unadjusted incidence rate ratio: 1.74 [95% CI: 0.77-3.78]).
CONCLUSIONS: Although we found a potentially fourfold increased rate of diabetes among children exposed to SGAs, the findings were inconsistent and depended on the comparison group and the outcome definition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22106077     DOI: 10.1542/peds.2011-0855

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  22 in total

1.  Off-label prescribing of psychotropic drugs in a Danish child and adolescent psychiatric outpatient clinic.

Authors:  Eva Skovslund Nielsen; Maja Hellfritzsch; Merete Juul Sørensen; Helle Rasmussen; Per Hove Thomsen; Torben Laursen
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-02-28       Impact factor: 4.785

2.  Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.

Authors:  Yoonyoung Park; Sonia Hernandez-Diaz; Brian T Bateman; Jacqueline M Cohen; Rishi J Desai; Elisabetta Patorno; Robert J Glynn; Lee S Cohen; Helen Mogun; Krista F Huybrechts
Journal:  Am J Psychiatry       Date:  2018-05-07       Impact factor: 18.112

Review 3.  Viral infection, inflammation and schizophrenia.

Authors:  Rachel E Kneeland; S Hossein Fatemi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-10       Impact factor: 5.067

4.  Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case-control study.

Authors:  Hankil Lee; Dong-Ho Song; Jin-Won Kwon; Euna Han; Min-Jung Chang; Hye-Young Kang
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-02-19       Impact factor: 4.785

5.  Decrease in Statewide Antipsychotic Prescribing after Implementation of Child and Adolescent Psychiatry Consultation Services.

Authors:  Rebecca P Barclay; Robert B Penfold; Donna Sullivan; Lauren Boydston; Julia Wignall; Robert J Hilt
Journal:  Health Serv Res       Date:  2017-04       Impact factor: 3.402

6.  Evaluation of monitoring for metabolic effects in children treated with second generation antipsychotics in a pediatric clinic.

Authors:  Brooke L Honey; Lourdes Ramos; Nancy C Brahm
Journal:  J Pediatr Pharmacol Ther       Date:  2013-10

Review 7.  Use of antipsychotic medications in pediatric populations: what do the data say?

Authors:  Robert B Penfold; Christine Stewart; Enid M Hunkeler; Jeanne M Madden; Janet R Cummings; Ashli A Owen-Smith; Rebecca C Rossom; Christine Y Lu; Frances L Lynch; Beth E Waitzfelder; Karen J Coleman; Karen A Coleman; Brian K Ahmedani; Arne L Beck; John E Zeber; Gregory E Simon
Journal:  Curr Psychiatry Rep       Date:  2013-12       Impact factor: 5.285

8.  Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.

Authors:  Drew E Winters; Sadaaki Fukui; Ellen Leibenluft; Leslie A Hulvershorn
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-04-30       Impact factor: 2.576

9.  Second-generation antipsychotic use among stimulant-using children, by organization of medicaid mental health.

Authors:  Brendan Saloner; Meredith Matone; Amanda R Kreider; M Samer Budeir; Dorothy Miller; Yuan-Shung Huang; Ramesh Raghavan; Benjamin French; David Rubin
Journal:  Psychiatr Serv       Date:  2014-11-17       Impact factor: 3.084

Review 10.  Addressing prediabetes in childhood obesity treatment programs: support from research and current practice.

Authors:  Matthew A Haemer; H Mollie Grow; Cristina Fernandez; Gloria J Lukasiewicz; Erinn T Rhodes; Laura A Shaffer; Brooke Sweeney; Susan J Woolford; Elizabeth Estrada
Journal:  Child Obes       Date:  2014-07-23       Impact factor: 2.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.